Advertisement
AXON vs BEAM
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Beam Therapeutics (BEAM) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) boasts a larger market capitalization of approximately $32 billion and positive earnings per share (EPS, a measure of profitability per share) of $1.53, contrasting with Beam Therapeutics' (BEAM) $3 billion cap and negative EPS of -$0.81.
- AXON has delivered stronger year-to-date (YTD, performance from January 1) returns of 29% compared to BEAM's 11%, though BEAM shows higher one-year gains of 55% versus AXON's 35%.
- Recent market activity has seen AXON pull back amid competition concerns, while BEAM benefits from positive clinical trial updates in its gene-editing pipeline.
- Both stocks trade in high-beta environments (AXON beta 1.43, BEAM 2.19; beta measures volatility relative to the market), but AXON's recurring software revenue provides more stability than BEAM's biotech risks.
- Upcoming earnings reports for both—AXON on May 6 and BEAM around May 5—could drive near-term volatility and clarify relative momentum.
Introduction
Axon Enterprise (AXON), a leader in public safety technology, and Beam Therapeutics (BEAM), a biotech innovator in base editing, represent distinct investment profiles in today's market. AXON offers exposure to hardware-software hybrids with recurring revenue, while BEAM taps into high-growth gene therapy potential. Traders seeking momentum plays and investors eyeing sector diversification will find this stock comparison valuable for assessing relative performance, risk-reward trade-offs, and positioning amid recent volatility. With both showing resilience in broader indices, understanding their trajectories aids informed decision-making in a dynamic environment.
AXON Overview and Recent Performance
Axon Enterprise (AXON) develops TASER devices, body cameras, and AI-enhanced software for law enforcement and public safety. In recent market activity, the stock has traded around $402, down from its 52-week high of $886 but above the low of $339, reflecting a year-to-date gain of 29%. Sentiment has been influenced by robust Q4 FY25 results, including 40% software revenue growth and EPS of $2.15 beating estimates, alongside innovations like an AI-powered 911 platform. However, recent weeks saw an approximately 19% pullback due to competition from AI peers and tariff concerns, prompting "buy the dip" discussions. High price-to-earnings (P/E, stock price divided by EPS) ratio of 263 signals growth expectations, supported by projected 27-30% revenue expansion in 2026.
BEAM Overview and Recent Performance
Beam Therapeutics (BEAM) pioneers base editing technologies for precise gene therapies targeting diseases like sickle cell. Shares recently hovered near $31, within a 52-week range of $15-$36, with YTD returns of 11% and one-year gains of 55%. Recent performance drew boosts from encouraging Phase 1/2 BEACON study results for Risto-cel and a TIME honor for base editing advancements, alongside Q4 profitability and a $500 million financing facility. Analyst views label it speculative, with negative EPS of -$0.81 and ongoing R&D cash burn, though $1.25 billion in cash provides runway. Volatility persists in the biotech sector, tempered by clinical catalysts.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and styles like swing trading or scalping on 15-60 minute intervals. These bots showcase impressive stats, including annualized returns from 24% to 163%, win rates of 51% to 88%, and profit factors up to 11.7, often with risk controls like 3% take-profit/2% stop-loss corridors. Focused on high-volatility themes such as semiconductors, AI infrastructure, space, and volatility plays, they trade sets of 3-18 tickers each, delivering profit-to-drawdown ratios exceeding 17 in top cases. Explore these curated tools to align with current market conditions and enhance your trading edge.
Head-to-Head Comparison
AXON and BEAM diverge sharply in business models: AXON's hybrid of hardware sales and SaaS-like subscriptions drives predictable growth (27-30% projected), while BEAM relies on milestone-based biotech revenue amid pipeline risks. Growth drivers contrast AXON's public safety moat and AI integrations against BEAM's clinical breakthroughs. Recent momentum favors BEAM's trial wins over AXON's dip, but AXON exhibits lower risk via profitability versus BEAM's losses. Sector exposure pits defense-tech stability against biotech's binary outcomes, with market sentiment leaning toward AXON's scale amid broader rotations.
Tickeron AI Verdict
Tickeron's AI models currently lean toward AXON with higher probability due to its trend consistency, recurring revenue stability, and superior YTD positioning relative to BEAM's higher-beta volatility and profitability gaps. Catalysts like upcoming earnings could shift dynamics, but AXON's established growth trajectory offers a more favorable risk-adjusted outlook in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and BEAM is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- BEAM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 6 bearish.
- BEAM’s TA Score: 4 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -9.13% price change this week, while BEAM (@Biotechnology) price change was -1.26% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.16%. For the same industry, the average monthly price growth was +2.06%, and the average quarterly price growth was +17.36%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
BEAM is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Aerospace & Defense (-1.16% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+0.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | BEAM | AXON / BEAM | |
| Capitalization | 35.6B | 2.99B | 1,192% |
| EBITDA | 320M | -349.25M | -92% |
| Gain YTD | -22.221 | 4.726 | -470% |
| P/E Ratio | 178.12 | N/A | - |
| Revenue | 2.98B | 164M | 1,819% |
| Total Cash | 737M | 1.21B | 61% |
| Total Debt | 1.83B | 251M | 728% |
AXON | BEAM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 66 | 100 | |
SMR RATING 1..100 | 82 | 93 | |
PRICE GROWTH RATING 1..100 | 60 | 47 | |
P/E GROWTH RATING 1..100 | 58 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BEAM's Valuation (27) in the null industry is somewhat better than the same rating for AXON (78) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that AXON’s stock grew somewhat faster than BEAM’s over the last 12 months.
AXON's SMR Rating (82) in the Biotechnology industry is in the same range as BEAM (93) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
BEAM's Price Growth Rating (47) in the null industry is in the same range as AXON (60) in the Biotechnology industry. This means that BEAM’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that AXON’s stock grew somewhat faster than BEAM’s over the last 12 months.
| AXON | BEAM | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | N/A |
| Stochastic ODDS (%) | 3 days ago 69% | 3 days ago 87% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 89% |
| MACD ODDS (%) | 3 days ago 83% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 67% | 3 days ago 83% |
| TrendMonth ODDS (%) | 3 days ago 72% | 3 days ago 83% |
| Advances ODDS (%) | 13 days ago 74% | 6 days ago 76% |
| Declines ODDS (%) | 3 days ago 69% | 3 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 69% | 3 days ago 86% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 67% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XITK | 194.16 | 1.92 | +1.00% |
| State Street® SPDR® FctSt Innvtv TechETF | |||
| PRFZ | 52.91 | 0.46 | +0.87% |
| Invesco RAFI US 1500 Small-Mid ETF | |||
| IDVZ | 35.08 | 0.24 | +0.68% |
| Polen International Div Inc ETF | |||
| GFEB | 43.76 | 0.12 | +0.28% |
| FT Vest U.S. Eq Mod Buffr ETF - Feb | |||
| FHDG | 36.00 | 0.09 | +0.25% |
| FT Vest U.S. Eq Qt Dyn Buffr ETF | |||
BEAM and
Correlation & Price change
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | -1.29% | ||
| CRSP - BEAM | 71% Closely correlated | -0.86% | ||
| EDIT - BEAM | 61% Loosely correlated | +2.46% | ||
| PRME - BEAM | 61% Loosely correlated | -1.60% | ||
| NTLA - BEAM | 59% Loosely correlated | -1.94% | ||
| AXON - BEAM | 57% Loosely correlated | -1.00% | ||
More | ||||